Biomarcadores de las Enfermedades Cardíacas
BIOMARCS
University of Lorraine
Nancy, FranciaPublicaciones en colaboración con investigadores/as de University of Lorraine (6)
2024
-
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
Hypertension Research
-
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Heart, Vol. 110, Núm. 19, pp. 1180-1187
2023
-
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694
2022
-
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331
2019
-
CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications
Hypertension, Vol. 73, Núm. 3, pp. 602-611
-
Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure
Heart, Vol. 105, Núm. 4, pp. 307-314